Search results for "Highlights"

Results 81 - 90 of about 406 for "Highlights".
Sort by: Relevance | Newest | Oldest

SGLT-2 inhibitors linked to more diabetic ketoacidosis vs. DPP-4 inhibitors or sulfonylureas

A retrospective study found that new users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors developed diabetic ketoacidosis at a rate of about 6 per 1,000 person-years, compared to 4.3 or 4.5 per 1,000 person-years with dipeptidyl peptidase-4 (DPP-4) inhibitors or sulfonylureas, respectively.
11 Mar 2022

Exercise and CBT are cost-effective for diabetes patients with depression

A study used simulation modeling to project the long-term effects of a three-month exercise and cognitive behavioral therapy (CBT) intervention for patients with type 2 diabetes and major depressive disorder. It found clear cost-effectiveness with the interventions alone or combined.
12 Mar 2021

KDIGO made 12 recommendations for managing diabetes with CKD

The kidney group's guideline supports metformin and sodium–glucose cotransporter-2 inhibitors as first-line therapies for patients with chronic kidney disease (CKD) based on consistent trial data showing their effectiveness, noted an ACP Journal Club commentary.
12 Mar 2021

Tirzepatide may improve glycemic control when added to insulin glargine in type 2 diabetes

An industry-sponsored phase 3 trial found statistically significant improvements in HbA1c level among patients with type 2 diabetes who had inadequate glycemic control on insulin glargine and were randomly assigned to subcutaneous tirzepatide once weekly versus placebo.
11 Feb 2022

Studies find link between metformin and reduced COVID-19 mortality, mixed results for DPP-4 inhibitors

Prior metformin use was associated with a threefold decrease in mortality from COVID-19 in one study of patients with type 2 diabetes, while three other studies found mixed results on whether dipeptidyl peptidase-4 (DPP-4) inhibitors affect COVID-19 outcomes.
12 Feb 2021

Neurologists update guideline on treatment of painful diabetic neuropathy

The updated guideline from the American Academy of Neurology supports offering tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and/or sodium channel blockers to reduce pain from diabetic neuropathy.
14 Jan 2022

Biomarker score predicts heart failure risk with diabetes and prediabetes

The score, which was based on cardiac troponin, N-terminal pro-B-type natriuretic peptide, C-reactive protein, and electrocardiography, could be used to target specific therapies to the highest-risk patients, study authors said.
8 Jan 2021

Surgical, drug treatments have similar outcomes in patients with vitreous hemorrhage from proliferative diabetic retinopathy

A randomized trial found equivalent improvements in visual acuity at two years with either therapy but identified some differences in outcomes that could help patients and clinicians choose a treatment method.
8 Jan 2021

Hospitalizations for diabetes complications fell, were replaced by other causes

An analysis of excess hospitalizations among people with diabetes in England from 2003 to 2018 found that diabetes caused fewer of their hospital stays, with respiratory disease and cancer becoming more predominant diagnoses.
10 Dec 2021

Patients with type 2 diabetes and all risk factors controlled still have increased CVD risk

Risk factor control was more strongly associated with mortality risk among patients with cardiorenal disease than those without, according to a retrospective British study.
11 Dec 2020

Result Page: Prev   4   5   6   7   8   9   10   11   12   13   Next